Hypnotics' association with mortality or cancer: a matched cohort study
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Objectives: An estimated 6%–10% of US adults took a hypnotic drug for poor sleep in 2010. This study extends previous reports associating hypnotics with excess mortality. Setting: A large integrated health system in the USA. Design: Longitudinal electronic medical records were extracted for a one-to-two matched cohort survival analysis. Subjects: Subjects (mean age 54 years) were 10 529 patients who received hypnotic prescriptions and 23 676 matched controls with no hypnotic prescriptions, followed for an average of 2.5 years between January 2002 and January 2007. Main outcome measures: Data were adjusted for age, gender, smoking, body mass index, ethnicity, marital status, alcohol use and prior cancer. Hazard ratios (HRs) for death were computed from Cox proportional hazards models controlled for risk factors and using up to 116 strata, which exactly matched cases and controls by 12 classes of comorbidity. Results: As predicted, patients prescribed any hypnotic had substantially elevated hazards of dying compared to those prescribed no hypnotics. For groups prescribed 0.4–18, 18–132 and >132 doses/year, HRs (95% CIs) were 3.60 (2.92 to 4.44), 4.43 (3.67 to 5.36) and 5.32 (4.50 to 6.30), respectively, demonstrating a dose–response association. HRs were elevated in separate analyses for several common hypnotics, including zolpidem, temazepam, eszopiclone, zaleplon, other benzodiazepines, barbiturates and sedative antihistamines. Hypnotic use in the upper third was associated with a significant elevation of incident cancer; HR=1.35 (95% CI 1.18 to 1.55). Results were robust within groups suffering each comorbidity, indicating that the death and cancer hazards associated with hypnotic drugs were not attributable to pre-existing disease. Conclusions: Receiving hypnotic prescriptions was associated with greater than threefold increased hazards of death even when prescribed <18 pills/year. This association held in separate analyses for several commonly used hypnotics and for newer shorter-acting drugs. Control of selective prescription of hypnotics for patients in poor health did not explain the observed excess mortality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“They found that the hazard of death was doubled in patients prescribed BZD compared to control patients [47].”
From Benzodiazepines: Uses, Dangers, and Clinical Considerations (2021) · cites this paper as [47]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There was an association between the prescription of anxiolytic drugs and mortality, resulting in 4 excess deaths in the anxiolytic drug group within an average of 7.6 years [47].”
From Benzodiazepines: Uses, Dangers, and Clinical Considerations (2021) · cites this paper as [47]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“One study further showed that the risk of dying is doubled in patients prescribed BZD compared with controls [47].”
From Benzodiazepines: Uses, Dangers, and Clinical Considerations (2021) · cites this paper as [47]
Experimental — accuracy not yet measuredIn the citing paper
“All of these interventions resulted in higher discontinuation rates than usual care. 37,38”
From Comparative efficacy of two interventions to discontinue long-term benzodiazepine use: cluster randomised controlled trial in primary care (2014) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Risk Factors for Falls among Elderly Persons Living in the Community
Tinetti, M. E., Speechley, M., & Ginter, S. F. (1988) · New England Journal of Medicine · doi:10.1056/nejm198812293192604 · Cited by 6,509
The global health burden of infection‐associated cancers in the year 2002
Parkin, D. M. (2006) · International Journal of Cancer · doi:10.1002/ijc.21731 · Cited by 2,932
Mortality Associated With Sleep Duration and Insomnia
Kripke, D. F., Garfinkel, L., Wingard, D. L., Klauber, M. R., & Marler, M. R. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.2.131 · Cited by 1,614
Self-citationSedative hypnotics in older people with insomnia: meta-analysis of risks and benefits
Glass, J., Lanctôt, K. L., Herrmann, N., Sproule, B. A., & Busto, U. E. (2005) · BMJ · doi:10.1136/bmj.38623.768588.47 · Cited by 1,161 · cited 2×
“21 30 Zolpidem has been shown to increase gastroesophageal regurgitation.”
BackgroundSmith, G. C. S., & Pell, J. P. (2003) · BMJ · doi:10.1136/bmj.327.7429.1459 · Cited by 1,157
Excess mortality in depression: a meta-analysis of community studies
Cuijpers, P., & Smit, F. (2002) · Journal of Affective Disorders · doi:10.1016/s0165-0327(01)00413-x · Cited by 775
Short and Long Sleep and Sleeping Pills: Is Increased Mortality Associated?
Kripke, D. F. (1979) · Archives of General Psychiatry · doi:10.1001/archpsyc.1979.01780010109014 · Cited by 660
Self-citationSmoking in relation to the death rates of one million men and women.
Ec, H. (1966) · PubMed · Cited by 648
Jacobs, G. D., Pace-Schott, E. F., Stickgold, R., & Otto, M. W. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.17.1888 · Cited by 579
Bronstein, A. C., Spyker, D. A., Cantilena, L. R., Green, J. L., Rumack, B. H., & Giffin, S. L. (2009) · Clinical Toxicology · doi:10.3109/15563650903438566 · Cited by 485
International Narcotics Control Board
United Nations Office on Drugs and Crime (2021) · Narcotic Drugs · doi:10.18356/9789210056373c026 · Cited by 454
The Efficacy and Safety of Drug Treatments for Chronic Insomnia in Adults: A Meta-Analysis of RCTs
Buscemi, N., Vandermeer, B., Friesen, C., Bialy, L., Tubman, M., Ospina, M., Klassen, T. P., & Witmans, M. (2007) · Journal of General Internal Medicine · doi:10.1007/s11606-007-0251-z · Cited by 448
Eckert, D. J., Owens, R. L., Kehlmann, G. B., Wellman, A., Rahangdale, S., Yim-Yeh, S., White, D. P., & Malhotra, A. (2011) · Clinical Science · doi:10.1042/cs20100588 · Cited by 367
Zolpidem Use and Hip Fractures in Older People
Wang, P. S., Bohn, R. L., Glynn, R. J., Mogun, H., & Avorn, J. (2001) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2001.49280.x · Cited by 272
Gustavsen, I., Bramness, J. G., Skurtveit, S., Engeland, A., Neutel, I., & Mørland, J. (2008) · Sleep Medicine · doi:10.1016/j.sleep.2007.11.011 · Cited by 201
Kyle, S. D., Morgan, K., Spiegelhalder, K., & Espie, C. A. (2011) · Sleep Medicine · doi:10.1016/j.sleep.2011.03.016 · Cited by 199
Mallon, L., Broman, J.-E., & Hetta, J. (2000) · International Psychogeriatrics · doi:10.1017/s1041610200006414 · Cited by 199
Amnestic sleep-related eating disorder associated with zolpidem
Morgenthaler, T. I., & Silber, M. H. (2002) · Sleep Medicine · doi:10.1016/s1389-9457(02)00007-2 · Cited by 185 · cited 1×
“23 e 25 Sleep apnoeas, in turn, may lead to motor vehicle 26 Hypnotics may cause somnambulistic night-eating syndromes resulting in poor diet and obesity 27 as well as other automaton-like behaviours, which can be dangerous.”
BackgroundMortality Hazard Associated with Prescription Hypnotics
Kripke, D. F., Klauber, M. R., Wingard, D. L., Fell, R. L., Assmus, J. D., & Garfinkel, L. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(97)00292-8 · Cited by 184
Self-citationSleep Disturbances and Cause-Specific Mortality: Results From the GAZEL Cohort Study
Rod, N. H., Vahtera, J., Westerlund, H., Kivimaki, M., Zins, M., Goldberg, M., & Lange, T. (2011) · American Journal of Epidemiology · doi:10.1093/aje/kwq371 · Cited by 177
Hypnosedative-Induced Complex Behaviours: Incidence, Mechanisms and Management
Dolder, C. R., & Nelson, M. H. (2008) · CNS Drugs · doi:10.2165/0023210-200822120-00005 · Cited by 172
Benzodiazepines, breathing, and sleep
Guilleminault, C. (1990) · The American Journal of Medicine · doi:10.1016/0002-9343(90)90282-i · Cited by 160
Greater incidence of depression with hypnotic use than with placebo
Kripke, D. F. (2007) · BMC Psychiatry · doi:10.1186/1471-244x-7-42 · Cited by 107
Self-citationPhillips, B. A., & Mannino, D. M. (2005) · SLEEP · doi:10.1093/sleep/28.8.965 · Cited by 104
Is usage of hypnotics associated with mortality?
Mallon, L., Broman, J., & Hetta, J. E. (2009) · Sleep Medicine · doi:10.1016/j.sleep.2008.12.004 · Cited by 101
Belleville, G. (2010) · The Canadian Journal of Psychiatry · doi:10.1177/070674371005500904 · Cited by 100
Zolpidem-polysomnographic study of the effect of a new hypnotic drug in sleep apnea syndrome
Cirignotta, F., Mondini, S., Zucconi, M., Gerardi, R., Farolfi, A., & Lugaresi, E. (1988) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(88)90212-2 · Cited by 96
The Relationship Between Insomnia and Mortality Among Community‐Dwelling Older Women
Althuis, M. D., Fredman, L., LANGENBERG, P. W., & Magaziner, J. S. (1998) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1998.tb04544.x · Cited by 81
Meta-Analyses of Hypnotics and Infections: Eszopiclone, Ramelteon, Zaleplon, and Zolpidem
Joya, F. L., Kripke, D. F., Loving, R. T., Dawson, A., & Kline, L. E. (2009) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.27552 · Cited by 62 · cited 1×
“32 Joya et al 32 inferred that increased upper respiratory irritation and infection might result from the increased gastroesophageal regurgitation caused by hypnotics.”
BackgroundSelf-citationAre sedatives and hypnotics associated with increased suicide risk of suicide in the elderly?
Carlsten, A., & Wærn, M. (2009) · BMC Geriatrics · doi:10.1186/1471-2318-9-20 · Cited by 62
Effect of Zolpidem on the Sleep Arousal Response to Nocturnal Esophageal Acid Exposure
Gagliardi, G. S., Shah, A. P., Goldstein, M., Denuna-Rivera, S., Doghramji, K., Cohen, S., & DiMarino, A. J. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.04.026 · Cited by 61
Zolpidem-induced amnesia and somnambulism: Rare occurrences?
Tsai, J., Yang, P., Chen, C., Chung, W., Tang, T., Wang, S.-Y., & Liu, J.-K. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.08.007 · Cited by 57
Effects of the use of hypnotics on cognition
Vermeeren, A., & Coenen, A. M. L. (2011) · Progress in brain research · doi:10.1016/b978-0-444-53817-8.00005-0 · Cited by 55
Allgulander, C., Ljungberg, L., & Fisher, L. D. (1987) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1987.tb02828.x · Cited by 49
Cardiovascular disease risk reduction with sleep apnea treatment
Jean‐Louis, G., Brown, C. D., Zizi, F., Ogedegbe, G. G., Boutin‐Foster, C., Gorga, J. A., & McFarlane, S. I. (2010) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.10.55 · Cited by 48
Possibility that certain hypnotics might cause cancer in skin
KRIPKE, D. F. (2008) · Journal of Sleep Research · doi:10.1111/j.1365-2869.2008.00685.x · Cited by 47
Self-citationZosel, A. E., Osterberg, E. C., & Mycyk, M. B. (2010) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3181d169ed · Cited by 30
Merlo, J., Hedblad, B., Ögren, M., Ranstam, J., Östergren, P. ‐., Ekedahl, A., Hanson, B. S., Isacsson, S., Liedholm, H., & Melander, A. (1996) · European Journal of Clinical Pharmacology · doi:10.1007/bf00226325 · Cited by 22
McCall, W. V., MS, Fleischer, A. B., & Feldman, S. R. (2002) · SLEEP · doi:10.1093/sleep/25.2.221 · Cited by 13
Research works printed but not linked: 1
- National Institute for Clinical Excellence, 2004, Guidance of the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia, Technol Appraisal, 77, 1
Cited by
Qaseem, A., Kansagara, D., Forciea, M. A., Cooke, M., Denberg, T. D., & for the Clinical Guidelines Committee of the American College of Physicians* (2016) · Annals of Internal Medicine · doi:10.7326/m15-2175 · Cited by 1,965
Depression in sleep disturbance: A review on a bidirectional relationship, mechanisms and treatment
Fang, H., Tu, S., Sheng, J., & Shao, A. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14170 · Cited by 1,141
Cognitive Behavioral Therapy for Chronic Insomnia: A Systematic Review and Meta-analysis
Trauer, J. M., Qian, M. Y., Doyle, J. S., Rajaratnam, S. M. W., & Cunnington, D. (2015) · Annals of Internal Medicine · doi:10.7326/m14-2841 · Cited by 1,053
Buysse, D. J. (2013) · JAMA · doi:10.1001/jama.2013.193 · Cited by 965
When the entire population is the sample: strengths and limitations in register-based epidemiology
Thygesen, L. C., & Ersbøll, A. K. (2014) · European Journal of Epidemiology · doi:10.1007/s10654-013-9873-0 · Cited by 570
Metadata
- Authors
- Kripke, D. F., Langer, R. D., & Kline, L. E.
- Affiliations
- Scripps Clinic (US)
- Corresponding author
- Kripke, Daniel F
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2012
- Volume
- 2
- Issue
- 1
- Pages
- e000850
- ISSN
- 2044-6055 (ISSN-L)
- PMC
- PMC3293137
- OpenAlex
- W2163579301
- Cited by
- 408
- References
- 39
- Citations by year
- 2026: 15 · 2025: 12 · 2024: 9 · 2023: 17 · 2022: 23 · 2021: 28 · 2020: 21 · 2019: 18 · 2018: 20 · 2017: 40 · 2016: 43 · 2015: 45 · 2014: 49 · 2013: 36 · 2012: 30
- FWCI
- 68.68
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- BMJ Open (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- University of California, San Diego
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- hypnotics, sleep aids, excess mortality, cancer incidence, benzodiazepines, barbiturates, zolpidem, temazepam, eszopiclone, zaleplon, dose-response relationship, prescribing patterns, comorbidities
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.